Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. by Kimmitt, P. T. et al.
458 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
Research
The associations between Escherichia coli
O157:H7 infection, hemorrhagic colitis, and
hemolytic uremic syndrome (HUS) were estab-
lished in the early 1980s (1,2). Shiga toxin-
producing E. coli (STEC) strains have since been
recognized as the cause of both outbreaks and
sporadic cases of diarrhea and HUS, involving
thousands of cases and numerous deaths (3).
Shiga toxins are key virulence factors in the
pathogenesis of STEC disease (3). The term Shiga
toxin (Stx) refers to two families of related toxins,
Stx/Stx1, which includes the classical Shiga toxin
produced by Shigella dysenteriae, and Stx2 (4).
The stx genes carried by STEC strains are, with
one possible exception (stx2e), encoded on
bacteriophage genomes integrated into the
bacterial chromosome. Stx2-producing STEC
strains are more closely associated with HUS
than are strains that produce only Stx1 (5,6).
Because antimicrobial agents may play a role
in the pathogenesis of severe STEC disease,
chemotherapy for STEC infections remains
controversial (7,8). The location of stx genes
(predominantly on  λ -like bacteriophage genomes
integrated into the chromosome of their host
bacterium) has important implications because
the induction of the SOS response, an extensively
characterized genetic regulatory mechanism,
induces high-level expression of previously silent
bacteriophage genes (9). Stx genes are coexpressed
with genes of the bacteriophage (10,11), and
certain quinolones (known to be potent SOS
inducers) induce increases in toxin (12,13) and
bacteriophage production (13) of two to three
orders of magnitude within 2 to 4 hours. The
potential importance of a link between the SOS
response and prophage induction for Stx1 and
Stx2 expression has been reinforced by recent
sequencing and pathogenicity studies (11,14,15).
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Toxin synthesis by Shiga toxin-producing Escherichia coli (STEC) appears to be
coregulated through induction of the integrated bacteriophage that encodes the toxin
gene. Phage production is linked to induction of the bacterial SOS response, a
ubiquitous response to DNA damage. SOS-inducing antimicrobial agents, particularly
the quinolones, trimethoprim, and furazolidone, were shown to induce toxin gene
expression in studies of their effects on a reporter STEC strain carrying a chromosome-
based stx2::lacZ transcriptional fusion. At antimicrobial levels above those required to
inhibit bacterial replication, these agents are potent inducers (up to 140-fold) of the
transcription of type 2 Shiga toxin genes (stx2); therefore, they should be avoided in
treating patients with potential or confirmed STEC infections. Other agents (20 studied)
and incubation conditions produced significant but less striking effects on stx2
transcription; positive and negative influences were observed. SOS-mediated induction
of toxin synthesis also provides a mechanism that could exacerbate STEC infections
and increase dissemination of stx genes. These features and the use of SOS-inducing
antibiotics in clinical practice and animal husbandry may account for the recent
emergence of STEC disease.Vol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 459
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We have constructed a genetically modified
derivative of a clinical isolate in which the genes
encoding both elements of the toxin (stx2AB)
were partially replaced with a lacZ reporter gene.
The product of this gene, ß-galactosidase, is
easily assayed and detected; its expression
reflects the transcriptional activity of the stx2
gene and can be visualized in simple agar plate
assays and quantified in biochemical assays. We
have extended our earlier observations on the
effects of quinolones on reporter expression by
this strain to include a wider range of
antimicrobial agents and the modulating effects
of different environmental conditions. Our
results show that several agents could increase
the amounts of toxin produced and that SOS-
inducing agents could play an important role in
the epidemiology of STEC infections.
Methods
Bacterial Strain and Growth Conditions
RV31, a strain of E. coli O157:H7 isolated
locally from a patient with hemorrhagic diarrhea,
was used to construct the reporter strain,
PK552(stx2A::lacZ), which contains a copy of the
E. coli lacZ gene transcriptionally fused to the
promoter region of stx2 on the chromosome.
The reporter strain construction, which in-
volved allelic exchange with a series of suicide
plasmid vectors, will be described elsewhere. In
the first step, the entire indigenous lac operon
and adjacent lacI gene were deleted to create a
Lac- strain. Then, most of the coding sequence
of the stx2A gene was replaced with a
promoterless E. coli lacZ gene, resulting in a
transcriptional fusion in which transcription of
the  lacZ reporter gene is controlled by stx2
regulatory mechanisms. The structure of the
final construct was confirmed by diagnostic
polymerase chain reaction, Southern blotting,
and nucleotide sequencing across the lacZ
insertion points.
Bacterial growth in the presence of antibiot-
ics was monitored by the Bioscreen C system and
associated Biolink software (Labsystems, Bas-
ingstoke, UK). This procedure allowed the
simultaneous measurement of growth in up to
200 tests by recording changes in optical density.
The stx2::lacZ reporter strain PK552 was grown
overnight at 37°C in Antibiotic Medium No. 3
(Oxoid, Basingstoke, Hampshire, UK). A 2-mL
aliquot of overnight culture was added to 100 mL
of prewarmed medium and incubated with
shaking at 37°C to an optical density at 600 nm
(OD600nm) of approximately 0.4. The culture was
then divided, and test antibiotics were added to
these aliquots from stock solutions. Aliquots of
these cultures (200 µL, 4 replicates) were then
injected into wells of honeycomb plates (Lab-
systems). The Biolink software was used to
program the Bioscreen C system to specify
wavelength, incubation temperature, length of
experiment, timing of readings, and the rate of
shaking of the cultures. The cultures were
incubated in the Bioscreen C system at 37°C with
continuous shaking, and OD600nm was recorded
every 15 min. MICs for selected antibiotics were
determined in the Bioscreen system by using the
inoculation pattern described above and by the
conventional agar dilution method.
Detection of ß-galactosidase Activity
An agar plate assay was used to screen the
responses of the reporter strain, PK552
(stx2A::lacZ), in producing ß-galactosidase activ-
ity in the presence of antibiotics. The assays were
performed by using Luria-Bertani (LB) agar
plates containing 20 µg/mL of the chromogenic
lactose analog X-gal (5-bromo-4-chloro-3-indolyl-
ß-D-galactopyranoside; Sigma, Poole, Dorset,
UK). An agar overlay of the PK552 reporter
strain was made by mixing 100 µL of an overnight
culture with 3 mL of molten LB top agar, cooled to
48°C, and pouring the mixture over the surface of
an LB agar plate. The plate was incubated with
antibiotic discs (see below) placed on the surface,
under the conditions specified. Expression of
ß-galactosidase was indicated by the enzymatic
cleavage of X-gal, resulting in a blue color, the
intensity of which related to the amount of
enzyme produced.
Microaerobic conditions (5% O2, 10% CO2,
85% N2) at 37°C were produced in a VAIN
incubator (Don Whitley Scientific, Shipley,
Yorkshire, UK). Microaerobic conditions at 42°C
and anaerobic conditions were produced in gas
jars by using Oxoid gas-generating kits according
to the manufacturer’s instructions.
Antibiotic discs (Oxoid/Unipath, UK) were
as follows: ofloxacin (5 µg), nalidixic acid
(30 µg), cinoxacin (100 µg), enrofloxacin (5 µg):
flumequine (30 µg), ciprofloxacin (1 µg),
perfloxacin (5 µg), norfloxacin (10 µg), amoxycillin/
clavulanic acid (20/10 µg), imipenem (10 µg),
aztreonam (30 µg), ceftazidime (30 µg), cefotaxime460 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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(30 µg), cefuroxime (5 µg), piperacillin/tazobactam
(10/75 µg), ampicillin (10 µg), cephalexin (30 µg),
chloramphenicol (30 µg), doxycycline (30 µg),
erythromycin (15 µg), trimethoprim (5 µg),
sulphamethoxazole (25 µg), furazolidone (50 µg),
amoxicillin (25 µg), novobiocin (30 µg), rifampin
(25 µg), gentamicin (10 µg), fosfomycin (200 µg)
(oral and systemic salts), polymyxin B (300 IU),
and metronidazole (50 µg).
The Bioscreen C system was also used to
measure total ß-galactosidase activity in whole
cultures of strain PK552 by orthonitrophenyl-ß-
D-galactoside (ONPG) assay (16). Aliquots
(20 µL, 4 replicates) of  culture were removed
from wells of the honeycomb plate and added to a
fresh plate. To this, 180 µL of Z buffer (60 mM
Na2HPO4 7H2O, 40 mM NaH2PO4 H2O, 10 mM
KCl, 1 mM MgSO4, and 50 mM ß-mercaptoethanol,
pH 7.0) containing 2 mg/mL lysozyme, 0.01%
sodium dodecyl sulfate (SDS), and 100  µg/mL
chloramphenicol was added to the cells. The plate
was incubated at 37°C for 30 min to lyse the cells
and placed on ice until use. The Bioscreen C
system was prewarmed to 28°C, and 40 µL of 4
mg/mL ONPG solution (made up in Z buffer) was
added to each well. Plates were incubated in the
Bioscreen C system at 28°C for 4 hours, and OD
was recorded at both 420 nm and 540 nm every 10
min. ß-galactosidase activity was determined by
using the linear portion of the corrected OD420 /
time relationship by the Miller formula, adjusted
for the sample volume (16). Replicate samples (at
least four in all assays reported) yielded mean
values with coefficients of variation <10% in all
cases.
Results
All the quinolones induced reporter expres-
sion, while only a few of the other agents had this
effect (Figure 1). The induction occurred in three
general patterns: a defined zone within the zone
of growth inhibition (quinolones), a defined zone
at the growth/no growth interface (furazolidone),
or a diffuse zone within the zone of inhibition
(trimethoprim). In addition, the incubation condi-
tions appeared to produce a background level of
induction or suppression. Microaerobic condi-
tions and to a lesser extent incubation at 30°C
were associated with background induction,
while anaerobic conditions and incubation at
42°C had a suppressive effect as determined by
the intensities of the blue zones. However, some
quinolone-mediated induction was always detect-
able, even under the most suppressive condition
(42°C). Induction by furazolidone and trimethop-
rim was, in general, similarly enhanced and
Figure 1. Zones of stx2 expression induced by various antimicrobial agents under different incubation conditions.
The disc-diffusion assay plates demonstrate background levels and zones of blue coloration related to reporter
gene β -galactosidase activity produced by our reporter strain. Digital images were acquired and processed
identically. Color was encoded by the CMYK system, and only the cyan component is displayed as a gray-scale
image. Blue zones appear as lighter areas of the plate, the intensity of which represents the blue intensity as
judged by direct comparison. Abbreviations: mO2, microaerobic and AnO2, anaerobic incubation conditions;
numbers denote incubation temperatures ( C). Left panel, quinolones (clockwise from top): ofloxacin, nalidixic
acid, cinoxacin, enrofloxacin, flumeqine, ciprofloxacin, perfloxacin, and norfloxacin. Right panel, other oral
agents (clockwise from top): trimethoprim, erythromycin, doxycycline, chloramphenicol, cephalexin, amoxycillin,
furazolidone, and sulphamethoxazole.Vol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 461
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Table. Induction of stx2 expression by antibiotics under different incubation conditionsa
Target of action                                               Incubation conditionsb
Agent (disc content mg/L) mO2/37 O2/37 mO2/42 AnO2/37 O2/30 O2/42 Zone patternc
  Background + - - - + -   NA
DNA Gyrase
  Quinolonesd + + + + + +/- >MIC
  Novobiocin (30) + - - - + - >MIC
Folate metabolism
  Trimethoprim (5) + + - + + - >MIC
  Smx (25) + + - + - - >MIC
DNA
  Metronidazole (50) - - - - - -   NA
  Furazolidone (50) + + - - + - =MIC
Cell envelope
  Cephalexin (30) + + - - +/- - =MIC
  Amoxycillin (25) + + - - - - =MIC
  Amoxy/Clav (20/10) +/- - - - - - =MIC
  Ampicillin (10) + + - - - - =MIC
  Pip/Taz (10/75) + + - - - - =MIC
  Imipenem (10) - - - - - -   NA
  Aztreonam (30) + + - - - - =MIC
  Cefuroxime (5) + + - - - - =MIC
  Ceftazidime (30) + + - - - - =MIC
  Cefotaxime (30) + + - - - - =MIC
  Fosfomycin (200) - - - - - -   NA
  Polymyxin B (300 IU) +/- - - - + - =MIC
Translation
  Gentamicin (10) - - - - - -   NA
  Chloramphenicol (30) - - - - - -   NA
  Doxycycline (30) - - - - - -   NA
  Erythromycin (15) - - - - - -   NA
Transcription
  Rifampin (25) - - +/- - - -   NA
aStx2 induction effects (zones of blue coloration, Figure 1): -, not detected, +/-, borderline induction, +, definite induction,  >MIC,
zone of induction within the zone of growth inhibition; =MIC, induction on the edge of the zone of inhibition; NA, not applicable;
Amoxy/Clav, amoxycillin/clavulanic acid; Pip/Taz, piperacillin/tazobactam; Smx, sulphamethoxazole.
bO2, aerobic; mO2 microaerobic; AO2, anaerobic/incubation temperature °C
cNote: The patterns indicated were detected in three separate experiments and recorded by two independent observers.
dThe quinolones tested are listed in the Materials and Methods section.
suppressed, although 42°C abolished all induc-
tion, and anaerobic conditions did not suppress
trimethoprim/sulphamethoxazole induction.
As a group, only the agents that inhibit
prokaryotic translation failed to induce reporter
expression under any condition tested (Table).
Like furazolidone, although less intensely,
several ß-lactam agents induced expression at
the growth/no growth interface. Imipenem (a
carbapenem) not only failed to induce expression
but also inhibited induction by the adjacent
monobactam, aztreonam (not shown), at
subgrowth-inhibitory levels. We subsequently
observed that this suppressive effect was
confined to ß-lactam-mediated induction (i.e.,
imipenem showed no suppressive effect against
quinolones, trimethoprim, or furazolidone). We
also noted an apparent inhibitory effect of
clavulanic acid on amoxycillin in the co-
amoxyclav combination and a requirement for
potentiating conditions (30°C, mAO2 37°C) for
detectable induction by novobiocin, polymyxin B,
and rifampin.
We examined some of the features of
induction by quantitative assay of ß-galactosi-
dase in cultures induced by exposure to
antibiotics in liquid medium (Figures 2 and 3).
The relationship of induction to MIC was
consistent with that observed in the plate assays.
Cefuroxime and furazolidone showed induction
at sub-MIC levels, while the highest levels of
induction with ofloxacin and trimethoprim were462 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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seen at supra-MIC exposure levels; the latter two
agents were clearly more potent inducers
(Figures 2 and 3). We also examined the effects of
fosfomycin (0.03-80 g/L) in this assay; no
inducing effect was detected.
The time course experiments (Figure 3)
confirm the relative inducing potencies (Figure 2)
and show that furazolidone-mediated induction
is complete by 8 h. Levels of furazolidone-induced
enzyme activity were lower at 24 h than at 4 h or
12 h. In contrast, trimethoprim and ofloxacin
induction rapidly increased up to 6 h and 8 h,
respectively, then continued to increase more
slowly until the final measurement at 12 h.
Additional expression induced by these two
agents continued up to 24 h (Figure 2), while
cefuroxime-induced expression occurred only
between 12 h and 24 h.
Discussion
These patterns of reporter gene expression
demonstrate that several antimicrobial agents
have the capacity to increase the amount of
Stx2 synthesized by our STEC strain. Levels of
ß-galactosidase expression in the reporter strain
are closely correlated with biologically active toxin
produced by the parental wild type strain (12).
The demonstrated link to de novo gene
expression distinguishes our study from earlier
work in which it could not be determined whether
increased toxin levels reflected release of
preformed toxin by cell lysis or increased
synthesis (17-20). The inductions we observed
show how certain agents and environmental
conditions may increase the amount of toxin in
infected persons and that, in the absence of
definitive clinical data, they provide a rational
basis for avoiding certain agents in treating
patients who may have STEC infections.
Several of the agents tested here—the
quinolones (21), trimethoprim (22), furazolidone,
and metronidazole (23)—have a recognized
capacity to induce bacterial SOS response, which
is initiated when damaged bacterial DNA
interacts with and activates the multifunctional
RecA protein. Activated RecA, in turn, causes the
degradation of two key repressor proteins, LexA
and CI. The resulting de-repression of genes
regulated by LexA leads to the temporary arrest
of DNA synthesis and cell division and the
activation of error-prone DNA repair. In strains
carrying an integrated λ -like bacteriophage,
cleavage of the CI phage repressor/activator
Figure 2. Dose-response characteristics of antibiotic-
induced expression of stx2::lacZ. Exponential-phase
inocula were exposed to antibiotics for 4 h (white bars)
or 24 h (black bars), and β -galactosidase activity was
determined at the end of these periods. Fold-increase =
Test activity (+ antibiotic)/control activity (- antibi-
otic). Note the difference in scale between upper and
lower panels. *MICs refer to the antibiotic concentra-
tions required to inhibit growth in the Bioscreen
system, using the same inoculation pattern as in the
antibiotic induction experiments. The values were
cefuroxime 10 g/L, furazolidone 32 g/L, trimethoprim
0.6 g/L and ofloxacin 0.05 g/L.
Figure 3. Time course of stx::lacZ  induction by
antibiotics. Exponential-phase cultures were exposed
to the antibiotics indicated for up to 12 h, and whole
culture  β -galactosidase activities were determined.
The exposure levels were cefuroxime 0.625 g/L
(MICx1/16), furazolidone 8 g/L (MICx1/4),
trimethoprim 0.6 g/L (1xMIC) and ofloxacin 0.1 g/L
(2xMIC).Vol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 463
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protein leads to the induction of previously silent
phage-encoded genes (in this case including
stx2A and stx2B), followed by production of phage
particles and host bacterial cell lysis (9).
The most potent SOS inducers, the quinolones
and trimethoprim, produced the most prominent
effects in both agar and liquid culture assays.
Metronidazole did not induce reporter expression
under the conditions tested; however, this agent
would not normally be expected to affect E. coli.
Another potent SOS inducer, mitomycin C, which
is known to increase toxin levels in vitro (24,25),
tests positive in agar and broth induction tests
with our reporter strain (results not shown).
The potential importance of the SOS response to
pathogenesis in vivo has recently been under-
lined by a study in which STEC strains with
mutations in recA, a critical gene for SOS
induction, were rendered avirulent in a mouse
50% lethal dose test (15).
The importance of antibiotic-induced Stx
expression would be reinforced if the implicated
agents were in some way associated with
occurrence or severity of STEC disease. The
results of available studies have conflicted with
regard to the influence of antibiotics. The age
groups studied, the timing of antibiotic therapy,
and the range of agents used complicate the
analyses. Nonetheless, use of quinolones and
trimethoprim/sulphamethoxazole (26,27) has
been implicated as a risk factor for HUS. In a
recent clinical study, children treated with
cephalosporins or trimethoprim-sulphamethox-
azole had, respectively, 13.4- and 17.7-fold
increases in risk for HUS (28). Our observations
suggest that the net effect of one of these agents
on the exposure of an infected patient to toxin
depends on the stage of the infection, the number
of organisms present at the time antibiotics are
administered, the immediate environmental
conditions of those organisms, and the time-
concentration profile and bactericidal effect of
the drug. This complex interplay of factors could
render an SOS-inducing antibiotic clinically
beneficial (e.g., if the numbers of infecting
organisms were insufficient to produce substan-
tial amounts of toxin and they were all killed by
the first dose), neutral, or disadvantageous in
different situations. Moreover, exposure of
patients to other potential SOS-inducing agents
(cf. 9,23) could further complicate the relation-
ship between antibiotic use and severe STEC
disease. A strong association between mitomycin
C administration and HUS was detected in a
study of “cancer-associated” HUS (29).
Grif and colleagues reported on the effects of
sub-MIC levels of 13 antibiotics on release of
biologically active toxin (as distinct from toxin gene
expression) by three STEC strains into culture
supernatants after overnight incubation (20).
These authors observed substantial interstrain
differences in the responses, as well as increased
levels of toxin after exposure to several agents
that had not previously been associated with
SOS-inducing activity. Grif et al. did not
distinguish between enhanced release of pre-
formed toxin and increased toxin production, and
the most potent inducing effects we have
observed were at suprainhibitory levels of
exposure. Nonetheless, we cannot rule out
interstrain differences in susceptibility to SOS
activation and the possibility that other
induction mechanisms may be involved. Our
observations on SOS induction by several
ß-lactam agents and the inhibitory effects of
imipenem appear pertinent. Suppression of toxin
expression by imipenem supports previous
observations on toxin release (30). Paired disc-
diffusion assays involving imipenem and other
recognized SOS-inducing antibiotics indicated
that this effect was confined to induction by
ß-lactam agents (Kimmitt, Harwood, and Barer,
unpubl data). This finding, combined with the
different time course of induction with ce-
furoxime, reinforces the view that there may be
induction pathways distinct from the SOS
response. Although the nature of the putative
alternate induction pathway(s) remains obscure,
the clear evidence for ß-lactam-mediated induc-
tion may contraindicate use of the implicated
agents in treating patients with STEC infection.
Although any increase in exposure of STEC-
infected persons to Shiga toxins seems undesir-
able, SOS-mediated induction seems particularly
hazardous because of its potential rapid effects.
We report kinetics (Figure 3) somewhat slower
than those we observed previously in the shaken
conical flask incubations (12). The rapid buildup
in toxin levels associated with SOS induction
could facilitate entry of toxin into the blood-
stream and subsequent disseminated effects on
the kidneys and other organs. SOS-mediated
induction also leads to dissemination of the toxin-
encoding bacteriophage.
Matsushiro et al. observed parallel increases
in toxin and bacteriophage counts in response to464 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
Research
norfloxacin (13), and we have made similar
observations with ofloxacin and trimethoprim
(Kimmit, Harwood and Barer, unpubl data).
Moreover, sequencing studies clearly indicate
that expression of stx2  and bacteriophage
genes is coordinately regulated (11,14). Hemor-
rhagic colitis and HUS attributable to STEC
were recognized after trimethoprim and the 4-
quinolones were introduced into human and
veterinary clinical practice, and the substantial
recent increase in reports of STEC disease
follows expanded use of fluoroquinolones.
Fluoroquinolones and trimethoprim have
been recommended for prophylaxis and treatment
of travelers’ diarrhea (31), and the former are
often used to treat severe bacterial enteric
infections. Our findings indicate that this approach
may be inappropriate if STEC infection is a
possibility. Furthermore, reports that certain
antimicrobial agents may ameliorate or reduce
symptoms or the frequency of life-threatening
complications in STEC infections provide an
incentive to find a rational basis for selection
(8,27). Our results suggest that agents with SOS-
inducing activity, antimicrobial or otherwise,
should be avoided (Table).
We conclude that SOS-mediated induction of
Shiga toxins and toxin–encoding bacteriophages
may contribute to the emerging epidemiologic
pattern of STEC disease. Many other bacterial
virulence determinants are encoded on lysogenic
bacteriophage genomes (32), and the issues
raised here may have public health and clinical
implications beyond the understanding of
STEC disease.
Acknowledgments
We thank D. Jenkins for providing strain RV31 from a
patient with hemorrhagic diarrhea.
This work was funded by The Department of Health,
London (DH 243).
Dr. Kimmitt is trained in medical microbiology and
molecular biology. He is currently studying the molecu-
lar biology of chlamydia infection at the London School
of Hygiene and Tropical Medicine.
References
  1. Karmali MA, Petric M, Lim C, Fleming PC, Steele BT.
Escherichia coli cytotoxin, haemolytic-uraemic syndrome,
and haemorrhagic colitis. Lancet 1983;2:1299-300.
  2. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG,
Davis BR, et al. Hemorrhagic colitis associated with a rare
Escherichia coli serotype. N Engl J Med 1983;308:681-5.
  3. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet
1998;352:1207-12.
  4. Acheson DW. Nomenclature of enterotoxins. Lancet
1998;351:1003.
    5. Scotland SM, Willshaw GA, Smith HR, Rowe B.
Properties of strains of Escherichia coli belonging to
serogroup O157 with special reference to production of
Vero cytotoxins VT1 and VT2. Epidemiol Infect
1987;99:613-24.
  6. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean
N, Kobayashi JM. Toxin genotypes and plasmid profiles as
determinants of systemic sequelae in Escherichia coli
O157:H7 infections. J Infect Dis 1989;160:994-8.
  7. Carter AO, Borczyk AA, Carlson JA, Harvey B, Hockin
JC, Karmali MA, et al. A severe outbreak of Escherichia
coli  O157:H7-associated hemorrhagic colitis in a
nursing home. N Engl J Med 1987;317:1496-500.
8. Proulx F, Seidman E. Is antibiotic therapy of mice and
humans useful in Escherichia coli O157:H7 enteritis?
European J Clin Microbiol Infect Dis 1999;18:533-4.
  9. Walker GC. The SOS response of Escherichia coli. In:
F.C. Neidhardt, editor. Escherichia coli and Salmonella.
Washington: ASM Press; 1996. p. 1400-16.
10. Muhldorfer I, Hacker J, Keusch GT, Acheson DW, Tschape
H, Kane AV. Regulation of the Shiga-like toxin II operon in
Escherichia coli. Infect Immun 1996;64:495-502.
11. Neely MN, Friedman DI. Functional and genetic
analysis of regulatory regions of coliphage H-19B:
location of shiga-like toxin and lysis genes suggest a
role for phage functions in toxin release. Mol Microbiol
1998;28:1255-67.
12. Kimmitt PT, Harwood CR, Barer MR. Induction of type
2 shiga toxin synthesis in Escherichia coli O157 by 4-
quinolones. Lancet 1999;353:1588-9.
13. Matsushiro A, Sato K, Miyamoto H, Yamamura T,
Honda T. Induction of prophages of enterohemorrhagic
Escherichia coli O157:H7 with norfloxacin. J Bacteriol
1999;181:2257-60.
14. Plunkett G, Rose DJ, Durfee TJ, Blattner FR. Sequence
of Shiga toxin 2 phage 933W from Escherichia coli
O157:H7: Shiga toxin as a phage late-gene product. J
Bacteriol 1999;181:1767-78.
15. Fuchs S, Muhldorfer I, Donohue-Rolfe A, Kerenyic M,
Emody L, Alexiev R, et al. Influence of RecA on in vivo
virulence and Shiga toxin 2 production in Escherichia
coli pathogens. Microb Pathog 1999;27:13–23.
16. Miller JH. Experiments in molecular genetics. Cold Spring
Harbor (NY): Cold Spring Harbor Laboratory; 1972.
17. Karch H, Strockbine NA, O’Brien AD. Growth of
Escherichia coli in the presence of trimethoprim-
sulfamethoxazole facilitates detection of Shiga-like
toxin producing strains by colony blot assay. FEMS
Microbiol Lett 1986;35:141-5.
18. Yoh M, Frimpong EK, Honda T. Effect of
antimicrobial agents, especially fosfomycin, on the
production and release of Vero toxin by enterohaem-
orrhagic Escherichia coli O157:H7. FEMS Immunol
Med Microbiol 1997;19:57-64.Vol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 465
Research
19. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG.
Effect of subinhibitory concentrations of antibiotics on
extracellular Shiga-like toxin-I. Infection 1992;20:25-9.
20. Grif K, Dierich MP, Karch H, Allerberger F. Strain-
specific differences in the amount of Shiga toxin
released from enterohaemorrhagic Escherichia coli
O157 following exposure to subinhibitory concentrations
of antimicrobial agents. Eur J Clin Microbiol Infect Dis
1998;17:761-6.
21. Drlica K, Zhao XL. DNA gyrase, topoisomerase IV, and the
4-quinolones. Microbiol Mol Biol Rev 1997;61:377-94.
22. Lewin CS, Amyes SG. The role of the SOS response in
bacteria exposed to zidovudine or trimethoprim. J Med
Microbiol 1991;34:329-32.
23. Quillardet P, Hofnung M. The SOS chromotest: a
review. Mutat Res 1993;297:235-79.
24. Yee AJ, De Grandis S, Gyles CL. Mitomycin-induced
synthesis of a Shiga-like toxin from enteropathogenic
Escherichia coli H.I.8. Infect Immun 1993;61:4510-13.
25. al-Jumaili I, Burke DA, Scotland SM, al-Mardini H,
Record CO. A method of enhancing verocytotoxin
production by Escherichia coli. FEMS Microbiol Lett
1992;72:121-5.
26. Pavia AT, Nichols CR, Green DP, Tauxe RV, Mottice S,
Greene KD, et al. Hemolytic-uremic syndrome during an
outbreak of Escherichia coli O157:H7 infections in
institutions for mentally retarded persons: clinical and
epidemiologic observations. J Pediatr 1990;116:544-51.
27. Dundas S, Todd WTA. Clinical presentation,
complications and treatment of infection with
verocytotoxin producing Escherichia coli. Challenges
for the clinician. J Appl Microbiol 2000;88:24S-30S.
28. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI.
The risk of the hemolytic-uremic syndrome after
antibiotic treatment of Escherichia coli O157:H7
infections. N Engl J Med 2000;342(26):1930-6.
29. Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R,
Keller J, et al. Cancer-associated hemolytic -uremic
syndrome: analysis of 85 cases from a national registry.
J Clin Oncol 1989;115:781-9.
30. Takahashi K, Narita K, Kato Y, Sugiyama T, Koide N,
Yoshida T, et al. Low-level release of Shiga-like toxin
(verocytotoxin) and endotoxin from enterohemorrhagic
Escherichia coli treated with imipenem. Antimicrob
Agents Chemother 1997;41:2295-6.
31. Health Information for International Travel 1999-
2000. Atlanta: Centers for Disease Control and
Prevention;1999. p. 168.
32. Cheetham BF, Katz ME. A role for bacteriophages in
the evolution and transfer of bacterial virulence
determinants. Mol Microbiol 1995;18:201-8.